Eli Lilly will likely draw investor focus on Monday as the company said its investigational once-weekly insulin efsitora alfa ...

But their budget expanded after pharmaceutical giant Eli Lilly announced on Mar. 1 that the monthly out-of-pocket prices of their insulin brands will soon be capped at $35 regardless of a person ...

Today, Lilly — the famous maker of weight-loss drug Zepbound and diabetes treatment Mounjaro — is the biggest health care stock on the S&P 500 with a market cap of almost $845.6 billion.

Drugmaker Eli Lilly on Thursday warned against using its diabetes and obesity drugs for “cosmetic” weight loss, as the medications have exploded in popularity, resulting in shortages. In an ...

Eli Lilly is selling to Amphastar Pharmaceuticals global rights to Baqsimi, an emergency treatment for severe hypoglycemia in diabetes patients. The deal come as Lilly turns its focus to novel ...

The drugmaker Eli Lilly is cutting the list prices for its most popular insulin products by 70 percent and capping out-of-pocket costs at $35 per month, the company said Wednesday, as pressure moun… ...

Eli Lilly is unveiling LillyDirect, a new digital healthcare platform for patients living with obesity, migraine and diabetes.LillyDirect offers disease management resources, including access to ...

Eli Lilly, one of the three makers of insulin products in the United States, is also making other moves toward affordability for people with diabetes. Health Care Eli Lilly cuts some older insulin ...

After recent moves by weight loss companies WW and Noom into telehealth prescribing, drugmaker Eli Lilly is starting a service that will connect people needing medications for obesity, diabetes ...

Eli Lilly & Co. says it’s cutting prices on its most prescribed insulin by 70% and expanding a program to cap out-of-pocket costs for the medication at $35 a month at participating pharmacies, a ...

With FDA clearance secured for its Bluetooth-connected insulin dose-tracking technology, Eli Lilly is ready to pick up the tempo. The Big Pharma plans to begin rolling out its Tempo diabetes ...

Eli Lilly said in its news release that it will also cut the price of its non-branded insulin, Insulin Lispro Injection, to $25 per vial effective on May 1, 2023, and will be cutting the cost of ...